Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - american depositary shares each representing one ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: GlobeNewswire
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of $240 – $260 million in 2025, representing 50% year-over-year growth at the midpoint -- -- Management to host a conference call today at 4:30 p.m. ET -- DUBLIN, Ireland, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a business update including preliminary estimates of fourth quarter and full year 2024 net revenue and cash, cash equivalents and marketable securities. "2024 was a pivotal year for Avadel, marked by consistent patient adoption of LUMRYZ and overwhelmingly positive feedback from both patients and provider
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Assessing Avadel Pharmaceuticals (AVDL) Valuation After Strong 1-Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic HypersomniaGlobeNewswire
- Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDLPR Newswire
- Form 8.3 [Yahoo! Finance]Yahoo! Finance
- Form 8.3 [Yahoo! Finance]Yahoo! Finance
AVDL
Earnings
- 8/7/25 - Beat
AVDL
Sec Filings
- 12/19/25 - Form DEFA14A
- 12/18/25 - Form 8-K
- 12/9/25 - Form DEFA14A
- AVDL's page on the SEC website